Podcasts | Accessible conversations on pharma's hot topics

Skip to main content

Monday 9 February 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Sales & Marketing

pharmaphorum podcast Episode 243, Lisa Sims, Novartis

On quality data for quality learnings, with Lisa Sims

Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & operations at Novartis, about personalising learning at scale.

Digital

pharmaphorum podcast Episode 242, Yann Gaston-Mathe, Iktos

JPM2026: Broadening AI drug discovery to include the lab, wi...

Yann Gaston-Mathe, founder and CEO of Iktos, discusses AI drug discovery's shift to real-world operations that are able to incorporate wet lab data.

Oncology

pharmaphorum podcast Episode 241, Mohit Manrao, AstraZeneca

On AI and equity in the cancer setting, with Mohit Manrao

Deep Dive editor Eloise McLennan speaks with Mohit Manrao, SVP, head of US oncology at AstraZeneca, and president of the AstraZeneca Foundation.

Digital

pharmaphorum podcast Episode 240, Andrew Beck, PathAI

JPM2026: AI diagnostics and translational research, with And...

On the sidelines of JPM2026, pharmaphorum spoke with Andrew Beck, co-founder and CEO at PathAI, about AI diagnostics in pathology.

R&D

pharmaphorum podcast Episode 239, Dr Jorg Schuttrumpf

Shaping the future of immunodeficiency care, with Dr Jörg Sc...

Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.

Oncology

pharmaphorum podcast Episode 126

Move over CAR-T: The potential of NK cells in cell therapy

The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren't the only option for cell th

Digital

pharmaphorum podcast episode 134a

Working for a mature form of genomic medicines

In a new episode of the pharmaphorum podcast, Rahul Kakkar, CEO of gene editing company Tome, speaks with web editor Nicole Raleigh about programmable genomic integration (PGI) technology.<

R&D

pharmaphorum podcast Episode 125

Challenges and opportunities in synthetic clinical trials

Of the many changes coming to clinical trials, one of the biggest potential paradigm shifts on the horizon is the elimination of placebo groups in some trials in favour of synthetic control

Load more results

Sales & Marketing

Sales & Marketing

HCP and patient

Sponsored

From Buzzword to Strategy: Reverba Global Talks Omnichannel ...

Sales & Marketing

pharmaphorum podcast Episode 243, Lisa Sims, Novartis

On quality data for quality learnings, with Lisa Sims

Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & operations at Novartis, about personalising learning at scale.

Digital

Digital

pharmaphorum podcast Episode 242, Yann Gaston-Mathe, Iktos

JPM2026: Broadening AI drug discovery to include the lab, wi...

Yann Gaston-Mathe, founder and CEO of Iktos, discusses AI drug discovery's shift to real-world operations that are able to incorporate wet lab data.

Digital

pharmaphorum podcast Episode 240, Andrew Beck, PathAI

JPM2026: AI diagnostics and translational research, with And...

On the sidelines of JPM2026, pharmaphorum spoke with Andrew Beck, co-founder and CEO at PathAI, about AI diagnostics in pathology.

Market Access

Market Access

Lady listening to audio

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

Market Access

pharmaphorum podcast Episode 210 - Neal Masia

Smoothing a contract pathway through uncertainty: In convers...

Today's podcast with Entity Risk's Neal Masia includes insights on the 340B Program, PBMs, and risk-based contracts.

Editor's Picks

White House's TrumpRx platform has arrived

Hims & Hers copies Novo Nordisk's new Wegovy pill

Lilly says 2026 looks good, as sales rocket in Q4

Fears US drug pricing deal will weigh heavy on the NHS

FDA launches pilot programme to boost US manufacturing

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

pharmaphorum podcast Episode 241, Mohit Manrao, AstraZeneca

On AI and equity in the cancer setting, with Mohit Manrao

Deep Dive editor Eloise McLennan speaks with Mohit Manrao, SVP, head of US oncology at AstraZeneca, and president of the AstraZeneca Foundation.

Oncology

pharmaphorum podcast Episode 238, Andrew Newland, ANGLE

Aligning with national efforts to modernise cancer diagnosti...

Andrew Newland, former CEO of ANGLE, explains why live cell liquid biopsies should become standard in oncology.

Oncology

pharmaphorum podcast Episode 229, Craig Eagle, Guardant Health

How blood tests can inform cancer treatment decisions, with ...

Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.

Patients

Patients

pharmaphorum podcast Episode 237, Vinay Patel

Rethinking prescription drug affordability, with Vinay Patel

Vinay Patel, an innovative pharmacist, discuss the intricacies of drug pricing and accessibility in the US.

Patients

pharmaphorum podcast Episode 234, Amy Bucher, Lirio

Delivering the right behavioural ingredients for the moment,...

Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.

Patients

pharmaphorum podcast Episode 228, Ruth Chambers, Raparu Consult CIC

The NHS, system burden, and a transformation prescription, w...

Dr Ruth Chambers OBE, co-director of Raparu Consult CIC and a visiting professor at Staffordshire University, discusses her book on the NHS.

R&D

R&D

pharmaphorum podcast Episode 239, Dr Jorg Schuttrumpf

Shaping the future of immunodeficiency care, with Dr Jörg Sc...

Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.

R&D

pharmaphorum podcast Episode 235, Markus Vossman, Illumina

On genomics, NGS, and doing much more good than bad, with Ma...

Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.

R&D

pharmaphorum podcast Episode 230, Benedict Cross, PhoreMost

Harnessing the cell's own degradation machinery, with Benedi...

Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.

Editor's Picks

White House's TrumpRx platform has arrived

Hims & Hers copies Novo Nordisk's new Wegovy pill

Lilly says 2026 looks good, as sales rocket in Q4

Fears US drug pricing deal will weigh heavy on the NHS

FDA launches pilot programme to boost US manufacturing

News

Lilly strikes $8.8bn-plus alliance with China's Innovent

Lilly strikes $8.8bn-plus alliance with China's Innovent

Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D with a $350m upfront payment.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company